

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/767,824
				Filing Date	January 29, 2004
				First Named Inventor	Cooperstone et al
				Group Art Unit	1614
				Examiner Name	R. Henley
Sheet	1	of	3	Attorney Docket Number	AM-101305USA
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2/3/known}			
	A	US-3,929,992	12-30-1975	Sehgal et al	
	B	US-3,993,749	11-23-1976	Sehgal et al	
	C	US-4,401,653	08-30-1983	Chee P. Eng	
	D	US-4,885,171	12-5-1989	Sehgal et al	
	E	US-5,078,999	01-07-1992	Warner et al	
	F	US-5,080,899	01-14-1992	Sturm et al	
	G	US-5,100,899	03-31-1992	Sir R. Calne	
	H	US-5,362,718	11-08-1994	Skotnicki et al	
	I	US-5,321,009	06-14-1994	Baeder et al	
	J	US-5,206,018	04-27-1993	Sehgal et al	
	K	US-5,286,730	02-15-1994	Caufield et al	
	L	US-5,286,731	02-15-1994	Caufield et al	
	M	US-5,288,711	02-22-1994	Mitchell et al	
	N	US-5,387,589	02-07-1995	Prasad S. Kulkarni	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ^{5/known}					
A	O	EP	0525960	B1	03-20-1996	American Home Products Corporation	
	P	PCT	WO 03/077915	A1	09-25-2003	Wyeth	
	Q	PCT	WO 01/97809	A2	12-27-2001	American Home Products Corporation	

Examiner Signature 

Date Considered

1/25/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

A check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/767,824
				Filing Date	January 29, 2004
				First Named Inventor	Cooperstone et al
				Group Art Unit	Ilei4
				Examiner Name	R. Henley
Sheet	3	of	3	Attorney Docket Number	AM-101305USA



OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column/issue number(s), publisher, city and/or country where published	T ²
	W	STARUCH ET AL, FK506 and Rapamycin Inhibit Murine T Cell Activation Through Different Mechanisms, The FASEB Journal, Vol. 3, No. 3 3411, (1989)	
	X	SEHGAL ET AL, Rapamycin (AY-22, 989), A New Antifungal Antibiotic, II. Fermentation, Isolation and Characterization, The Journal of Antibiotics, Vol. XXVIII No. 10, pp. 727-732 (October 1975)	
	Y	VEZINA ET AL, Rapamycin (AY-22,989), A New Antifungal Antibiotic I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle, The Journal of Antibiotics, Vol. XXVIII No. 10, pp. 721-726 (October 1975)	
	Z	BAKER ET AL, Rapamycin (AY-22,989), A New Antifungal Antibiotic, III. In Vitro and In Vivo Evaluation, The Journal of Antibiotics, Vol. XXXI, No. 6, pp. 539-545, (June 1978)	
	AA	MARTEL ET AL, Inhibition of the Immune Response by Rapamycin, a New Antifungal Antibiotic, Can. J. Physiol. Pharmacol. Vol.55, pp. 48-51 (1977)	
	BB	DUMONT ET AL, Rapamycin Blocks the Immunosuppressive Effect of FK506 But Not That of Cyclosporin A, FASEB JOURNAL, 5256, Vol. 3, No. 4, (1989)	
	CC	R. Y. CALNE ET AL, Prolonged Survival of Pig Orthotopic Heart Grafts Treated with Cyclosporin A, Lancet, pp. 1183-1185, (June 3, 1978)	

Examiner Signature	<i>R. Henley</i>	Date Considered	1/25/06
--------------------	------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours (and by the USPTO to process) an application. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/767,824
				Filing Date	January 29, 2004
				First Named Inventor	Cooperstone
				Group Art Unit	1614
				Examiner Name	R. Henley
Sheet	1	of	1	Attorney Docket Number	AM-101305USA

NONPATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
	HH	SHIBATA NORIKUNI , <u>Antifibrosis effect of interferongamma (IFNgamma) and rapamycin (Rapa) in immortal human hepatic stellate cells</u> , Database Biosis Online!, 2002, pp. 185-197, Database accession no. PREV200300151275, ISSN: 0386-5924, vol. 28, pp. 185-197, Biosciences Information Service, Kawasaki Igakkai Shi [Abstract]				
	II	S. JAIN, ET AL. , <u>Rapamycin Reduces Expression of Fibrosis-Associated Genes in an Experimental Model of Renal Ischaemia Reperfusion Injury</u> , Transplantation Proceedings, February 2001, pp. 556-558, vol. 22, no. 1-2, ISSN: 0041-1345, Elsevier Science, Inc., New York, NY				
	JJ	YOSHIHIDE ARISAKA , <u>Effects of interferon-gamma and rapamycin on transforming growth factor-beta-induced liver fibrosis in an organotypic slice culture</u> , Database Chemabs Online!, 2003, pp. 597-603, Database accession no. 2004:146496, ISSN: 0029-0424, vol. 62(11), Nihon Daigaku Igakkai [Abstract]				
	KK	L. LOPEZ-LAZARRO, ET AL. , <u>F. LOKIEC, ET AL.</u> , H.C. SWAISLAND, ET AL., U. MAYER, ET AL., L. PLASSWILM, ET AL., G. CARTEI, ET AL., F. LOKIEC, ET AL., M. AIROLDI, ET AL., J. BONI, ET AL., O. TOMOYUKI, ET AL., O. JUAN, ET AL., T. OE, ET AL., <u>Pharmacokinetics poster session (12 individual poster titles)</u> , European Journal of Cancer, October 2001, pp. S66-S69, vol. 37, Pergamon Press, Oxford, GB [Posters]				
Examiner Signature			Date Considered	1/25/06		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


PTO/SB/08B (08-00)

Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/767,824
				Filing Date	January 29, 2004
				First Named Inventor	Cooperstone et al
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	AM-101305USA

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column/issue number(s), publisher, city and/or country where published	T ²
<i>JF</i>	EE	SHIBATA ET AL, Establishment of an Immortalized Human Hepatic Stellate Cell Line to Develop Antifibrotic Therapies, Cell Transplantation, Vol. 12, pp. 499-507, (2003)	
<i>JF</i>	FF	FRIEDMAN ET AL, The Virtuosity of Hepatic Stellate Cells, Gastroenterology, Vol. 117, No. 5, pp. 1244-1246, (November 1999)	
<i>JF</i>	GG	ZHU ET AL, Rapamycin Inhibits Hepatic Stellate Cell Proliferation in Vitro and Limits Fibrogenesis in an In Vivo Model of Liver Fibrosis, Gastroenterology 117, 5, pp. 1198-1204, (November 1999)	

Examiner Signature:  Date Considered: 1/26/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file
(and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours
to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the
individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent
to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR
COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.